Xoma traded at $19.49 this Tuesday December 6th, decreasing $0.03 or 0.15 percent since the previous trading session. Looking back, over the last four weeks, Xoma lost 11.63 percent. Over the last 12 months, its price fell by 12.25 percent. Looking ahead, we forecast Xoma to be priced at 20.38 by the end of this quarter and at 18.46 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 163.72 -0.22 -0.13% 34.74%
Agenus 2.56 -0.23 -8.24% -20.74%
Agios Pharmaceuticals 28.60 -1.20 -4.03% -12.51%
Ardelyx 1.83 -0.03 -1.61% 26.21%
Bluebird Bio 7.83 -0.18 -2.25% -21.31%
BioMarin Pharmaceutical 102.22 -1.31 -1.27% 18.69%
Celldex Therapeutics 36.34 -0.32 -0.87% -6.27%
Chimerix 2.15 -0.07 -3.15% -65.54%
Curis 0.76 -0.02 -2.24% -84.55%
Emergent BioSolutions 12.19 0.40 3.39% -71.11%
Intercept Pharmaceuticals 13.99 -0.33 -2.30% -17.46%
Incyte Corp 82.54 -1.54 -1.83% 23.69%
Life Technologies 2.07 -0.22 -9.61% -74.73%
Eli Lilly 368.70 -0.75 -0.20% 50.42%
MacroGenics 6.07 -0.31 -4.86% -64.73%
Novartis 85.28 -0.52 -0.61% 13.93%
Novartis 90.74 -0.22 -0.24% 12.47%
Pfizer 49.71 -1.02 -2.01% -3.89%
Prothena 58.55 -1.84 -3.05% 18.62%
Regeneron Pharmaceuticals 747.47 -7.98 -1.06% 17.70%
Teva Pharmaceutical Industries 8.55 -0.07 -0.81% 1.54%
Xoma 19.49 -0.03 -0.15% -12.25%

Indexes Price Day Year
USND 11015 -225.05 -2.00% -29.78%
US2000 1813 -27.65 -1.50% -19.58%

Xoma
XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that is licensed to pharmaceutical or biotechnology companies. Its product candidates include PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism; XMetA, an insulin receptor-activating antibody, and X213, an allosteric inhibitor of prolactin action. It has a range of antibody discovery and development technologies, which includes antibody discovery advanced platform technologies (ADAPT), ModulX and OptimX. The ADAPT technology includes phage display libraries integrated with yeast and mammalian display. Its ModulX technology enables the identification of allosteric antibodies for positive or negative modulation of biological pathways. The OptimX technology is used for optimizing biophysical properties of antibodies.